A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile
- PMID: 19665608
- DOI: 10.1016/j.vaccine.2009.07.076
A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile
Erratum in
- Vaccine. 2010 Dec 6;28(52):8352
- Vaccine. 2012 Dec 14;30(52):7667
Abstract
Priorix-Tetra (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix) and varicella (Varilrix) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
